Andrii Gorelik
@andriigorelik.bsky.social
340 followers 250 following 16 posts
Sir Henry Wellcome Fellow | Oxford with Ivan Ahel & Harvard with Steve Gygi Molecular mechanisms of cysteine modifications | GlcNAc and ADP-ribose Previously: The Francis Crick Institute/Imperial College London (postdoc), University of Dundee (PhD)
Posts Media Videos Starter Packs
Pinned
andriigorelik.bsky.social
New paper! We uncover mechanistic insights into the crosstalk between AHR (aryl hydrocarbon receptor, a transcription factor) and PARP7 (a nuclear enzyme that performs protein ADP-ribosylation). Both are promising cancer drug targets.

Big thanks to all co-authors!

www.pnas.org/doi/10.1073/...
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
www.pnas.org
andriigorelik.bsky.social
Out in @natcomms.nature.com: Cryo-EM structure of the pseudo-HAT-containing O-GlcNAcase!

Especially exciting since multiple companies are developing O-GlcNAcase inhibitors for Alzheimer's disease (tau is O-GlcNAcylated). Glad to have a small contribution in this story.
Congrats to all authors!
Multi-domain O-GlcNAcase structures reveal allosteric regulatory mechanisms - Nature Communications
This work reveals how a regulatory domain in O-GlcNAc hydrolase (OGA) shapes enzyme flexibility and activity, uncovering mechanisms that help maintain O-GlcNAc balance in cells.
www.nature.com
Reposted by Andrii Gorelik
harvardcellbio.bsky.social
New work from our own Chouchani Lab finds that LRRC58 is the substrate adaptor of an E3 ubiquitin ligase that mediates proteasomal degradation of CDO1, the rate-limiting enzyme of the catabolic shunt of cysteine to taurine in response to altered Cysteine levels. www.nature.com/articles/s41...
Covariation MS uncovers a protein that controls cysteine catabolism - Nature
A mass spectrometry-based approach globally identifies protein regulators of metabolism and reveals the role of LRRC58 in controlling cysteine catabolism.
www.nature.com
Reposted by Andrii Gorelik
nizet.bsky.social
Robert Redford (RIP) survived a childhood bout of polio though bedridden for 2 weeks

In 2014, he directed a short film on the architecture and mission of La Jolla's Salk Institute—honoring founder Jonas Salk, inventor of the polio vaccine that has saved countless lives, and architect Louis Kahn
CATHEDRALS OF CULTURE - Clip ROBERT REDFORD: Salk Institute -- La Jolla, California, USA - HD
YouTube video by neueroadmovies
youtu.be
Reposted by Andrii Gorelik
ahellab.bsky.social
A few years back we discovered a dual hybrid protein modification composed of an ADP-ribose dinucleotide and the ubiquitin moieties (ADPr-Ub). Here you can read our review that will give you an update on this increasingly popular topic:
rdcu.be/eETIT
The rise of ADP-ribose–ubiquitin
Nature Structural & Molecular Biology - Post-translational modifications show mechanistic crosstalk, exemplified by the ADP-ribose–ubiquitin hybrid signal, in which one post-translational...
rdcu.be
Reposted by Andrii Gorelik
sonjalorenzlab.bsky.social
Delighted to share our work on cellular ubiquitination of drug-like compounds by HUWE1 - a surprising journey! Kudos to all contributors & first authors, Barbara Orth and Pavel Pohl. Sincere thanks to @ireserra.bsky.social#NatCommun for expertly guiding the winding publishing path.
rdcu.be/eDzPk
Selective ubiquitination of drug-like small molecules by the ubiquitin ligase HUWE1
Nature Communications - Ubiquitination is a versatile modification system in eukaryotic cells. Here, the authors unveil that the ubiquitin ligase HUWE1 can modify drug-like small-molecule...
rdcu.be
Reposted by Andrii Gorelik
mjafreeman.bsky.social
Are you a postdoc interested in the mechanisms of disease?

Do you have a great record and an exciting vision?

Come and start your own lab @dunnschool.bsky.social by applying for sponsorship for early career fellowships.

Deadline 30th September...pass it on!

www.path.ox.ac.uk/work-with-us...
Group Leader Career Development Fellowships - Dunn School
Are you an early career researcher interested in the cell or molecular mechanisms underlying disease? Do you have an outstanding record and an innovative research plan?
www.path.ox.ac.uk
andriigorelik.bsky.social
Congratulations to first authors Gregor Lueg, James Zhang, Monica Faronato and big thanks to all co-authors for being amazing colleagues and collaborators!

Special thanks to Ed Tate and Dinis Calado for supervising this exciting project!
andriigorelik.bsky.social
Finally, we show that an orally bioavailable NMTi eliminates MYC-deregulated tumours in vivo without overt toxicity. MYC oncogene is deregulated in >50% of cancers but is notoriously difficult to target. Our discovery of the MYC-NMTi synthetic lethality circumvents this obstacle.
andriigorelik.bsky.social
Fortuitously, we discover that a patient mutation in NDUFAF4, associated with a neurological disorder called the Leigh syndrome, also leads to loss of myristoylation on NDUFAF4, its degradation and therefore dysfunctional respiratory complex I.
andriigorelik.bsky.social
Mechanistically, NMTi-induced mitochondrial failure is concurrent with loss of myristoylation on respiratory complex I assembly factor NDUFAF4 with its subsequent proteasomal degradation via the glycine N-degron mechanism.
andriigorelik.bsky.social
Using proteomics, we discovered that NMTi cause mitochondrial dysfunction (complex I defects) in high-MYC cancer cells.
andriigorelik.bsky.social
We screened hundreds of cancer cell lines using a potent and selective N-myristoyltransferase inhibitor (NMTi) and found a strong correlation between increased NMTi sensitivity and MYC deregulation with death of high (vs low) MYC cancer cells.
Reposted by Andrii Gorelik
jomaalab.bsky.social
Want to know how lipidation of some nascent chains takes place by NMT2-- Check our latest work on how NAC couples Protein Synthesis with Nascent Polypeptide Myristoylation on the Ribosome out today @embojournal.org‬: www.embopress.org/doi/full/10....
Reposted by Andrii Gorelik
Reposted by Andrii Gorelik
ardemp.bskyverified.social
I still can’t believe that all NIH grants to my colleagues at Harvard and Harvard Medical School have been nullified. And that, as a nation, we’re somehow okay with this illegal, arbitrary, and petty act. Just think of the consequences: scientists, students, and patients will all suffer.
andriigorelik.bsky.social
An amazing paper from van der Heden and Ahel groups! They use clever chemistry to identify RNF114 as a dual ADP-ribose-Ubiquitin reader involved in the DNA damage response! Congratulations to first authors Max, @chatrin-c.bsky.social and Rishov. Happy to have a small contribution in this story
Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose - Nature Communications
Deltex E3s modify ADP-ribosylated targets with ubiquitin, creating a hybrid modification whose readers remains unknown. Here, the authors synthesise a non-hydrolysable probe that mimics the modificati...
www.nature.com
Reposted by Andrii Gorelik
erictopol.bsky.social
This is wild!
Engineering E. coli bacteria to turn plastic waste into paracetamol (Tylenol)
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Andrii Gorelik
andriigorelik.bsky.social
Big thanks to all co-authors at FGC in Cambridge, Hull, Oslo, NCI Frederick and of course @ahellab.bsky.social @dunnschool.bsky.social! I had a lot of fun doing proteomics in Steve Gygi’s lab @harvardcellbio.bsky.social funded by Sir Henry Wellcome Fellowship - thanks to @wellcometrust.bsky.social!
andriigorelik.bsky.social
Plus, our CRISPR screen identified SOCS3 knockout as a new synthetic lethal interaction with PARP7i. Curiously, SOCS3 is also linked to AHR signalling.
andriigorelik.bsky.social
Transcriptomics is typically used to study transcription factors, but we took a different approach — examining proteome changes following PARP7 inhibition and AHR activation. This revealed post-translational events that contribute to the synthetic lethality via combined PARP7i and AHR activation.